See Article on Page 991.
Version of Record online: 20 SEP 2007
Copyright © 2007 American Association for the Study of Liver Diseases
Volume 46, Issue 4, pages 957–959, October 2007
How to Cite
Geppert, C. M. A. and Arora, S. (2007), Widening the door: The evolution of hepatitis C treatment in patients with psychiatric disorders. Hepatology, 46: 957–959. doi: 10.1002/hep.21891
Potential conflict of interest: Dr. Arora is on the speaker's bureau of and received grants from Roche Pharmaceuticals and Schering-Pharmaceuticals. He also received grants from Vertex Pharmaceuticals and Valeant Pharmaceuticals.
- Issue online: 25 SEP 2007
- Version of Record online: 20 SEP 2007
- 5Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. HEPATOLOGY 2007; 46. DOI: 10.1002/hep.21791., , , , , , et al.
- 6Management of hepatitis C. NIH Consens Statement 1997; 15: 1–41.
- 8Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101: 2254–2262., , , , , , et al.Direct Link:
- 17National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Government Printing Office; 1979.